Paclitaxel neurotoxicity: Clinical and neurophysiological study of 23 patients

Italian Journal of Neurological Sciences

Volumn 18, Issue 2, 1997, Pages 73-79

  Pace, A ^b   Bove, L ^b   Aloe, A ^a   Nardi, M ^b   Pietrangeli, A ^a   Calabresi, F ^a   Innocenti, P ^b   Jandolo, B ^b  

^a Servizio di Neurologia   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

distal axonopathy; neurotoxicity; paclitaxel; platinum compounds

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MUSCLE POTENTIAL; NERVE POTENTIAL; NEUROPATHY; NEUROPHYSIOLOGY; NEUROTOXICITY; OVARY CANCER; PARESTHESIA; SYMPTOM;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE WEAKNESS; NERVOUS SYSTEM; NEUROTOXINS; PACLITAXEL; SURAL NERVE;

EID: 0030926947     PISSN: 03920461     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01999566     Document Type: Article

References (32)

1. CHAUDHRY V, ROWINSKY EK, SARTORIUS SE, DONEHOWER RC, CORNBLATH DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol, 1994; 35: 304-311.
2. DYCK PJ, SHERMAN WR, HALLCHER LM. Human diabetic endoneurial sorbitol, fructose and myo-inositol related to sural nerve morphometry. Ann Neurol, 1980; 8: 590-596.
3. DONEHOWER RC, ROWINSKY EK, GROCHOW LB, LONGNECKER SL, ETTINGER S. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep, 1987; 71: 1171-1177.
4. DONEHOWER RC, ROWINSKY EK. An overview of experience with taxol in the U.S.A. Cancer Treat Rev, 1993; 19: 63-78.
5. EINZIG AL, WIERNIK PH, SASLOFF J, RUNOWICZ CD, GOLDBERG GL. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol, 1992; 10: 1748-1753.
6. ETTINGER DS. Overview of Paclitaxel (taxol) in advanced lung cancer. Sem Oncol, 1993; 20 (3): 46-49.
7. FORASTIERE AA. Use of Paclitaxel (taxol) in squamous cell carcinoma of the head and neck. Sem Oncol, 1993; 20(3): 56-60.
8. HAMERS FPT, GISPEN WH, NEIJT JP. Neurotoxic side effects of cisplatin. Eur J Cancer, 1991; 27(3): 372-376.
9. KRARUP-HANSEN A, FUGLEHOM K, HELWEG-LARSEN S. et al. Examination of distal involvement in cisplatin- induced neuropathy in man. Brain, 1993; 116: 1017-1041.
10. LIPTON RB, APFEL SC, DUTCHER JP. Taxol produces a predominantly sensory neuropathy. Neurology, 1989; 39: 368-373.
11. McGuiRE WP, ROWINSKY EK, ROSENSHEIN NB. et al. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasm. Ann Inter Med, 1988; 111: 273-279.
12. MOLLMAN JE, HOGAN WM, GLOVER DJ, McCLUSKEY LF. Unusual presentation of cisplatinum neuropathy. Neurology, 1988; 38: 488-490.
13. MOLLMAN JE. Cisplatin neurotoxicity. N Engl J Med, 1990; 332, 2: 126-127.
14. MURPHY WK, FOSSELLA FV, WINN RJ. Phase II study of taxol in patients with untreated non-small cell lung cancer. J Natl Cancer Inst, 1993; 85: 384-388.
15. OKEN MM. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 1982; 5: 649-655.
16. PACE A, BOVE L, PIETRANGELI A, INNOCENTI P, JANDOLO B. Docetaxel neuropathy. Neurology, 1996; 47 (Letter): 615.
17. PIETRANGELI A, PACE A, JANDOLO B. Neuropatia da Cisplatino. Riv Neurobiologia, 1990; 36 (1): 13-17.
18. POSTMA TJ, VERMORKEN JB, LIEFTING AIM, PINEDO HM, HEIMANS JJ. Paclitaxel induced neuropathy. Ann Oncol, 1995; 6: 489-494.
19. ROWINSKY EK, CAZENAVE LA, DONEHOWER RC. Taxol: a novel investigational antimicrotubule agent. JNCI, 1990; 82: 1247-1259.
20. ROWINSKY EK, EISENHAUER EA, CHAUDHRY V, ARBUCK SG, DONEHOWER RC. Clinical toxicities encountered with paclitaxel (TAXOL). Sem Oncol, 1993; 20, 4(3): 1-15.
21. ROWINSKY EK, CHAUDHRY V, FORASTIERE A. et al. Phase I and pharmacologie study of Paxlitaxel and cisplatin with granulocyte colony- stimulating factor: Neuromuscular toxicity is dose-limiting. ] Clin Oncol, 1993; 11, 10: 2010-2020.
22. SAROSY G, KOHN E, STONE DA. et al. Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol, 1992; 10: 1165-1170.
23. SCHAUMBURG HH, SPENCER PS. Toxic neuropathies. Neurology, 1978; 29: 429-431.
24. SCHIFF PB, FANT J, HORWITZ SB. Promotion of microtubule assembly in vitro by Taxol. Nature, 1979; 22: 665667.
25. SEIDMAN AD, NORTON L, REICHMAN BS. Preliminary experience with Paclitaxel (taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Sem Oncol, 1993; 20(3): 40-45.
26. SWASH M, SCHWARZ MS. Neuromuscular Disease, Chapter 7, Springer Verlag, Berlin, 1988: 113-123.
27. SWENERTON K, ElSENHAUER EA, TEN BOKKEL HUININK W. et al. Taxol in relapsed ovarian cancer: high vs low doses and short vs long infusion: A European-Canadian study coordinated by NCl Canada Clinical Trials Groups. Proc Am Soc Clin Oncol, 1993; 12: 256.
28. THOMPSON SW, DAVIS LE, KORNFELD M, HILGERS, STANDEFER JC. Cisplatin neuropathy: Clinical, Electrophysiologic, morphologic and toxicologie studies. Cancer, 1984; 54: 1269-1275.
29. VUORINEN VS, ROYTTA M. Taxol-induced neuropathy after nerve crush: long-term effects on Schwann and endoneurial cells. Acta Neuropathol, 1990; 79: 653-662.
30. VUORINEN VS, ROYTTA M. Taxol-induced neuropathy after nerve crush: long-term effects on regenerating axons. Acta Neuropathol, 1990; 79: 663-667.
31. WHO Handbook for reporting results of cancer treatment, WHO offset Publication N. 48, Ginevra.
32. WlERNICK PH, SCHWARTZ EL, STRAUMAN JJ, BUTCHER JP, LIPTON RB and ELISABETH PAIETTA. Phase I clinical and pharmacokinetic study of Taxol. Cancer Res, 1987; 47: 2486-2493.